Trial reportClinical pharmacology and therapeutics2010
Hepatic clearance, but not gut availability, of erythromycin is altered in patients with end-stage renal disease.
Trial report in Clinical pharmacology and therapeutics, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 68 citations in OpenAlex.
- Pharmacokinetics of tedizolid in subjects with renal or hepatic impairment.Antimicrobial agents and chemotherapy · 2014Trial
- Comprehensive clinical and metabolomics profiling of COVID-19 Mexican patients across three epidemiological waves.Frontiers in molecular biosciences · 2025Article
- Population Pharmacokinetics, Pharmacogenomics, and Adverse Events of Osimertinib and its Two Active Metabolites, AZ5104 and AZ7550, in Japanese Patients with Advanced Non-small Cell Lung Cancer: a Prospective Observational Study.Investigational new drugs · 2023Observational
- Potential Plasma Metabolite Biomarkers of Diabetic Nephropathy: Untargeted Metabolomics Study.Journal of personalized medicine · 2022Article
- Association of CYP3A5 polymorphisms and parathyroid hormone with blood level of tacrolimus in patients with end-stage renal disease.Clinical and translational science · 2021Article
- Identification of Antibiotics in Surface-Groundwater. A Tool towards the Ecopharmacovigilance Approach: A Portuguese Case-Study.Antibiotics (Basel, Switzerland) · 2021Article
- End-stage renal disease reduces the expression of drug-metabolizing cytochrome P450s.Pharmacological reports : PR · 2020Article
- A multicenter, phase I, pharmacokinetic study of osimertinib in cancer patients with normal renal function or severe renal impairment.Pharmacology research & perspectives · 2020Article
- Simultaneous Assessment of Hepatic Transport and Metabolism Pathways with a Single Probe Using Individualized PBPK Modeling ofThe Journal of pharmacology and experimental therapeutics · 2019Article
- Improved Predictions of Drug-Drug Interactions Mediated by Time-Dependent Inhibition of CYP3A.Molecular pharmaceutics · 2018Article
- BDDCS, the Rule of 5 and drugability.Advanced drug delivery reviews · 2016Review
- Drug Transporters and Na+/H+ Exchange Regulatory Factor PSD-95/Drosophila Discs Large/ZO-1 Proteins.Pharmacological reviews · 2015Review
- Clinical manifestation of macrolide antibiotic toxicity in CKD and dialysis patients.Clinical kidney journal · 2014Article
- Inhibition of human drug-metabolising cytochrome P450 and UDP-glucuronosyltransferase enzyme activities in vitro by uremic toxins.European journal of clinical pharmacology · 2014Article
- Effects of chronic kidney disease and uremia on hepatic drug metabolism and transport.Kidney international · 2014Review
- Article
- The role of BCS (biopharmaceutics classification system) and BDDCS (biopharmaceutics drug disposition classification system) in drug development.Journal of pharmaceutical sciences · 2013Review
- Effects of uremic toxins on transport and metabolism of different biopharmaceutics drug disposition classification system xenobiotics.Journal of pharmaceutical sciences · 2011Article
- A Synopsis of Clinical Pharmacokinetic Alterations in Advanced CKD.Seminars in dialysisReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
Nonrenal clearance of drugs can be significantly lower in patients with end-stage renal disease (ESRD) than in those with normal renal function. Using erythromycin (ER) as a probe compound, we investigated whether this decrease in nonrenal clearance is due to reduced hepatic clearance (CL(H)) and/or gut metabolism. We also examined the potential effects of the uremic toxins 3-carboxy-4-methyl-5-propyl-2-furan propanoic acid (CMPF) and indoxyl sulfate (Indox) on ER disposition. Route-randomized, two-way crossover pharmacokinetic studies of ER were conducted in 12 ESRD patients and 12 healthy controls after oral (250 mg) and intravenous (125 mg) dosing with ER. In patients with ESRD, CL(H) decreased 31% relative to baseline values (0.35 +/- 0.14 l/h/kg vs. 0.51 +/- 0.13 l/h/kg, P = 0.01), with no change in steady-state volume of distribution. With oral dosing, the bioavailability of ER increased 36% in patients with ESRD, and this increase was not related to changes in gut availability. As expected, plasma levels of CMPF and Indox were significantly higher in the patients than in the healthy controls. However, no correlation was observed between CL(H) of ER and the levels of uremic toxins.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.